Analyst Expectations For Zimmer Biomet Holdings's Future
Portfolio Pulse from Benzinga Insights
Zimmer Biomet Holdings (NYSE:ZBH) has been analyzed by 17 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target has decreased by 5.59% to $121.35. Analysts have mostly lowered their price targets, reflecting a cautious outlook. Despite positive revenue growth, Zimmer Biomet's financial metrics like ROE and ROA lag behind industry averages.
October 14, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Zimmer Biomet Holdings has seen a decrease in the average 12-month price target by 5.59% to $121.35, with analysts predominantly lowering their ratings. Despite a 3.87% revenue growth, the company's ROE and ROA are below industry averages, indicating potential challenges in financial performance.
The decrease in the average price target and the predominance of lowered ratings suggest a negative short-term outlook. The company's financial metrics, such as ROE and ROA, underperforming industry averages, further support this cautious sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100